Atrium Medical Corporation has completed patient enrolment for a study of the Atrium iCAST Balloon Expandable Covered Stent for the treatment of patients with iliac artery occlusive disease.

The prospective multi-centre clinical trial will evaluate the safety and efficacy of the Atrium iCAST Balloon Expandable Covered Stent, in which the stent will be used to re-open the blocked iliac artery to restore blood flow to the legs from the aorta.

The primary endpoint of the study will be a composite of occurrence of death within 30 days and target site revascularisation or restenosis within nine months post-procedure.

Iliac artery occlusive disease is a form of peripheral arterial disease, which is characterised by intermittent upper and lower leg pain, and affects over eight million people in the US.